Kringle Pharma is a late-stage regenerative medicine biopharmaceutical venture focused on developing recombinant human HGF (Hepatocyte Growth Factor) protein therapeutics for intractable and rare diseases. The company has established a proprietary pharmaceutical-grade manufacturing platform for recombinant HGF protein and is conducting multiple clinical trials targeting conditions including acute spinal cord injury, ALS, vocal cord scarring, and acute kidney injury. Its business model combines self-commercialization with sales partnerships (e.g., Maruishi Pharmaceutical) and active pharmaceutical ingredient supply to overseas partners such as Claris Biotherapeutics.
Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.
Free Demo (No Time Limit, 10 Companies) →Kringle Pharma is a late-stage regenerative medicine biopharmaceutical venture focused on developing recombinant human HGF (Hepatocyte Growth Factor) protein therapeutics for intractable and rare diseases. The company has established a proprietary pharmaceutical-grade manufacturing platform for recombinant HGF protein and is conducting multiple clinical trials targeting conditions including acute spinal cord injury, ALS, vocal cord scarring, and acute kidney injury. Its business model combines self-commercialization with sales partnerships (e.g., Maruishi Pharmaceutical) and active pharmaceutical ingredient supply to overseas partners such as Claris Biotherapeutics.
Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.
Free Demo (No Time Limit, 10 Companies) →